Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About

The Fed thinks biotech stocks are overvalued. Here's where they're wrong.

Jul 19, 2014 at 9:11AM

In the Fed's Monetary Policy Report submitted July 15th, Fed chair Janet Yellen called out social media and biotech stocks as having valuations that appear "substantially stretched" (i.e. overvalued). We asked our top contributors for stocks which they view as well-or-under-valued -- biotech stocks the Fed is just wrong about. Below are their thoughts.

George BudwellWhile I agree with Janet Yellen's comments regarding biotech valuations for the most part, there are notable exceptions worth checking out. I think the recombinant nanoparticle vaccine maker Novavax (NASDAQ:NVAX) is one such company. Despite sporting a market cap close to $1 billion on a fully diluted basis, the stock looks fairly valued, in my opinion.

My optimism is based on the company's diverse clinical pipeline that has racked up positive results over the past two years. Chief among them, I think investors should keep a close eye on Novavax's experimental vaccine for respiratory syncytial virus, or RSV. According to the World Health Organization, there are 64 million new cases of RSV every year, and no prophylactic vaccine exists for the majority of patient populations.

Novavax's plan is to develop the vaccine for a host of at-risk populations, including pregnant women, infants, young children, and the elderly. To gain an understanding of the vaccine's potential market opportunity, I think an apt comparison is Pfizer's megablockbuster Prevnar for pneumococcal disease. Viewed this way, Novavax's present market cap looks like it accurately reflects the company's value proposition and current level of risk. 

Todd CampbellI don't agree with the Fed on Opthotech (NASDAQ:OPHT), an emerging biotech working on a treatment for age-related macular degeneration, or AMD.

Aging baby boomers are spiking demand for currently approved AMD treatments, including Novartis' Lucentis and Regeneron's Eylea. Lucentis', which is sold by Novartis overseas and by Roche in the U.S., generated sales of $2.4 billion for Novartis last year and $500 million for Roche in the first quarter. Eylea sales also impressed, notching $1.4 billion for Regeneron last year and $218 million during the first quarter for Bayer, its international partner.

Rather than displacing those blockbusters, Opthotech's Fovista hopes to make them work better. In phase 2 trials, patients taking Opthotech's Fovista alongside Lucentis' saw their vision improve by 10.6 letters on a standard eye chart, versus 6.5 letters when taking Lucentis alone.

That efficacy suggests that Fovista alone could have blockbuster potential that justifies its current $1 billion market cap, but Opthotech is even more intriguing now that Novartis' has paid Opthotech $200 million up front and agreed to $1 billion in milestones just Fovista's non-U.S. rights.

Brian Orelli: It's difficult to find value in this market for biotechs that have near term catalysts, but if you're willing to buy and hold for awhile, it's still possible to find attractive biotechs.

That's the situation with Sarepta Therapeutics (NASDAQ:SRPT), which is developing a Duchenne muscular dystrophy drug called eteplirsen. Based on the phase 2 data, it's hard to believe the drug doesn't work, but because of the limited number of patients in the study -- just six in the treatment group -- the Food and Drug Administration may not be willing to accept the data for an accelerated approval. Sarepta plans to give it a shot, applying to the FDA by year end.

Worst case scenario, the FDA tells Sarepta that the drug isn't approvable until a confirmatory phase 3 trial is completed, potentially pushing an approval into 2016. If you can wait that long -- and tolerate a potential drop if the accelerated approval doesn't come through -- Sarepta should produce solid multi-year returns.

Given the unmet need in Duchenne muscular dystrophy, it's not hard to see sales of eteplirsen approaching $1 billion annually. At a P/S of five, Sarepta Therapeutics market cap could reach $5 billion, over five times where it is now. Even if you factor in some dilution to raise capital, the risk-reward looks reasonable.

A blockbuster opportunity even Janet Yellen would call undervalued.
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell, George Budwell, and Brian Orelli have no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers